TargetBeta
NECTIN4
nectin cell adhesion molecule 4 · also nectin-4, PRR4, LNIR, PVRL4 · V-set domain containing
10 programs in company-led studies act on NECTIN4, from 10 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 2010 running | – | NCIt |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 1414 running | – | the company's pipeline |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 1313 running | – | NCIt |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 66 running | – | NCIt |
| zelenectide pevedotinrule | BicycleTx | phase 2 | 55 running | BTC | NCIt |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 54 running | – | NCIt |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | Avenzo Therapeutics | phase 2 | 11 running | TACSTD2 | NCIt |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | Innate Pharma | phase 1 | 11 running | – | NCIt |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | Rondo Therapeutics | phase 1 | 11 running | CD28 | NCIt |
| CT-202rule | Context Therapeutics | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Carcinoma, Transitional Cell, 5 programs
- Urinary Bladder Neoplasms, 4 programs
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Squamous Cell Carcinoma of Head and Neck, 3 programs
- Triple Negative Breast Neoplasms, 3 programs
- Uterine Cervical Neoplasms, 3 programs
- Neoplasms, 2 programs
- Breast Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
- Non-Muscle Invasive Bladder Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026notiretatug rezetecan · Jiangsu HengRui Medicine · phase 3 · NCT06915142
- Dec 31, 2026enfortumab vedotin · Astellas Pharma · phase 4 · NCT06862219
- Dec 31, 2026bulumtatug fuvedotin · Mabwell (Shanghai) Bioscience · phase 3 · NCT06079112
- Jan 2027zelenectide pevedotin · BicycleTx · phase 2 · NCT04561362
- Jan 16, 2027Sutantatug Envedotin · CSPC Pharmaceutical Group · phase 3 · NCT06265727
- Jul 30, 2027Anti-nectin-4 Antibody-drug Conjugate MK-3120 · Merck · phase 2 · NCT07222488
- Apr 2028Anti-nectin-4 Antibody-drug Conjugate IPH4502 · Innate Pharma · phase 1 · NCT06781983
- Feb 28, 2029Anti-nectin-4/CD28 Bispecific Antibody RNDO-564 · Rondo Therapeutics · phase 1 · NCT07218003
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.